Abiraterone, an androgen synthesis inhibitor with antiandrogen properties, targets the AR by further suppression of available androgens in the tumor microenvironment (6) and has demonstrated clinical benefit in both CRPC (7, 8) and HSPC (9). The gene discussed is AR; the disease is neoplasm.